Mr. Oren Shuster reports

IM CANNABIS TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON MONDAY, MARCH 31 2025 AT 9:00AM ET

IM Cannabis Corp. will release operational and financial results for the fourth quarter and full year 2024 ended Dec. 31, 2024, on Monday, March 31, 2025, before market open.

The company will host a Zoom conference on the same day at 9 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register. All relevant information will be sent upon registration.

If you are unable to join live, a recording of the call will be available on the company's website within 24 hours after the call.

About IM Cannabis Corp.

IM Cannabis is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company's focus is to achieve sustainable and profitable growth in its highest-value markets, Israel and Germany. The company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IM Cannabis ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The company also operates medical cannabis retail pharmacies, on-line platforms, distribution centres and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.